MX2013001237A - Compuestos inhibidores del virus de la hepatitis c. - Google Patents
Compuestos inhibidores del virus de la hepatitis c.Info
- Publication number
- MX2013001237A MX2013001237A MX2013001237A MX2013001237A MX2013001237A MX 2013001237 A MX2013001237 A MX 2013001237A MX 2013001237 A MX2013001237 A MX 2013001237A MX 2013001237 A MX2013001237 A MX 2013001237A MX 2013001237 A MX2013001237 A MX 2013001237A
- Authority
- MX
- Mexico
- Prior art keywords
- hepatitis
- virus inhibitors
- compounds
- virus
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Abstract
La presente invención se refiere a compuestos, composiciones y métodos para el tratamiento de la infección del virus de la hepatitis C (HVC). También se describen composiciones farmacéuticas que contienen tales compuestos y métodos para usar estos compuestos en el tratamiento de la infección por HCV.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2010/044356 WO2012018325A1 (en) | 2010-08-04 | 2010-08-04 | Hepatitis c virus inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013001237A true MX2013001237A (es) | 2013-05-28 |
MX337936B MX337936B (es) | 2016-03-29 |
Family
ID=43640063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013001237A MX337936B (es) | 2010-08-04 | 2010-08-04 | Compuestos inhibidores del virus de la hepatitis c. |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP2601188B1 (es) |
JP (1) | JP5596861B2 (es) |
KR (1) | KR20140045903A (es) |
CN (1) | CN103153986B (es) |
AU (1) | AU2010358561B2 (es) |
BR (1) | BR112013002729A2 (es) |
CA (1) | CA2807305A1 (es) |
EA (1) | EA022127B1 (es) |
IL (1) | IL224298A (es) |
MX (1) | MX337936B (es) |
SG (1) | SG187183A1 (es) |
WO (1) | WO2012018325A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8673954B2 (en) * | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8354419B2 (en) | 2009-07-16 | 2013-01-15 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
WO2011119853A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
CA2809261A1 (en) | 2010-08-26 | 2012-03-01 | Rfs Pharma, Llc | Potent and selective inhibitors of hepatitis c virus |
US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2012158861A2 (en) | 2011-05-18 | 2012-11-22 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives |
WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9073943B2 (en) | 2012-02-10 | 2015-07-07 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
JP6069492B2 (ja) * | 2012-04-25 | 2017-02-01 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | C型肝炎ウイルス阻害剤 |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
CN105530933B (zh) | 2013-07-17 | 2018-12-11 | 百时美施贵宝公司 | 用于治疗hcv的包含联苯衍生物的组合产品 |
WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2018212162A1 (ja) | 2017-05-17 | 2018-11-22 | 株式会社トクヤマ | ジアミノベンゼン化合物の製造方法 |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
KR20210025517A (ko) | 2018-06-28 | 2021-03-09 | 가부시끼가이샤 도꾸야마 | α-아지도아닐린 유도체 또는 α,α'-디아지드 유도체의 제조 방법 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830905A (en) * | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
AU2003261434A1 (en) | 2002-08-12 | 2004-02-25 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of hcv replication |
WO2004026318A1 (ja) * | 2002-09-20 | 2004-04-01 | Kirin Beer Kabushiki Kaisha | α-グリコシルセラミドを有効成分とするC型肝炎ウイルス抑制剤 |
GB2438802A (en) | 2005-02-28 | 2007-12-05 | Univ Rockefeller | Structure of the hepatitis C virus NS5A protein |
US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8147818B2 (en) * | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8865756B2 (en) * | 2008-12-03 | 2014-10-21 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
TWI438200B (zh) * | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
-
2010
- 2010-08-04 CA CA2807305A patent/CA2807305A1/en not_active Abandoned
- 2010-08-04 MX MX2013001237A patent/MX337936B/es active IP Right Grant
- 2010-08-04 JP JP2013523129A patent/JP5596861B2/ja not_active Expired - Fee Related
- 2010-08-04 KR KR1020137005316A patent/KR20140045903A/ko active IP Right Grant
- 2010-08-04 CN CN201080069468.6A patent/CN103153986B/zh not_active Expired - Fee Related
- 2010-08-04 BR BR112013002729A patent/BR112013002729A2/pt not_active IP Right Cessation
- 2010-08-04 AU AU2010358561A patent/AU2010358561B2/en not_active Ceased
- 2010-08-04 EP EP10740116.8A patent/EP2601188B1/en not_active Not-in-force
- 2010-08-04 EA EA201370017A patent/EA022127B1/ru not_active IP Right Cessation
- 2010-08-04 SG SG2013005558A patent/SG187183A1/en unknown
- 2010-08-04 WO PCT/US2010/044356 patent/WO2012018325A1/en active Application Filing
-
2013
- 2013-01-17 IL IL224298A patent/IL224298A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20140045903A (ko) | 2014-04-17 |
IL224298A (en) | 2015-08-31 |
AU2010358561B2 (en) | 2016-06-02 |
CN103153986B (zh) | 2014-11-05 |
BR112013002729A2 (pt) | 2016-05-31 |
JP5596861B2 (ja) | 2014-09-24 |
EP2601188A1 (en) | 2013-06-12 |
EP2601188B1 (en) | 2017-10-18 |
EA201370017A1 (ru) | 2013-05-30 |
SG187183A1 (en) | 2013-02-28 |
AU2010358561A1 (en) | 2013-03-21 |
WO2012018325A1 (en) | 2012-02-09 |
MX337936B (es) | 2016-03-29 |
JP2013532725A (ja) | 2013-08-19 |
EA022127B1 (ru) | 2015-11-30 |
CA2807305A1 (en) | 2012-02-09 |
CN103153986A (zh) | 2013-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2012000264A1 (en) | Hepatitis c virus inhibitors | |
TN2012000214A1 (en) | Hepatitis c virus inhibitors | |
MX2013001579A (es) | Inhibidores del virus de la hepatitis c | |
MY152971A (en) | Hepatitis c virus inhibitors | |
MX2011008045A (es) | Inhibidores del virus de la hepatitis c. | |
MX2013001237A (es) | Compuestos inhibidores del virus de la hepatitis c. | |
MX2010008749A (es) | Inhibidores del virus de la hepatitis c. | |
MX2010008531A (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
HK1125576A1 (en) | Hepatitis c virus inhibitors | |
MX2010008699A (es) | Derivados heterociclicos como inhibidores de virus de la hepatitis c. | |
MX2010008863A (es) | Imidazolil-bifenil-imidazoles como inhibidores del virus de la hepatisis c. | |
HK1144935A1 (en) | Hepatitis c virus inhibitors | |
EA201391152A1 (ru) | Ингибиторы вируса гепатита с | |
MX2012008221A (es) | Inhibidores de virus flaviviridae. | |
MX2012008211A (es) | Inhibidores de virus flaviviridae. | |
MX2012000959A (es) | Inhibidores de los virus flaviviridae. | |
BR112013028679A2 (pt) | inibidores do vírus da hepatite c | |
PH12015500814A1 (en) | Hepatitis c virus inhibitors | |
MX2013004906A (es) | Nuevos inhibidores especificos de la proteasa ns3 de hcv. | |
TN2013000335A1 (en) | Hepatitis c virus inhibitors | |
TN2013000453A1 (en) | Hepatitis c virus inhibitors | |
UA113048C2 (xx) | Противірусні сполуки | |
MY163245A (en) | Hepatitis c virus inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |